Anthem Biosciences Limited

As of June 30, 2026, Anthem Biosciences Limited carries a market capitalization of 434.12B, placing it among publicly traded companies globally. Its enterprise value stands at 434.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Anthem Biosciences Limited's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Anthem Biosciences Limited has 563.38M shares outstanding.

As of June 30, 2026, Anthem Biosciences Limited trades at a trailing price-to-earnings ratio of 75.20.

As of June 30, 2026, Anthem Biosciences Limited trades at an EV/EBITDA multiple of 56.49 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 21.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 68.81 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 434.12B versus a market cap of 434.12B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 6.38M in revenue per employee across its workforce of 3,136.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Anthem Biosciences Limited recorded 2.07B in income tax expense. That works out to an effective tax rate of 26.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.83B, leaving 5.76B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Anthem Biosciences Limited's stock has gained approximately 7.90% over the past 52 weeks. The 50-day moving average sits at 888.99, while the 200-day moving average is 761.11.

Over the twelve months ended June 30, 2026, Anthem Biosciences Limited generated 20.02B in revenue and converted that into 5.76B in net income, yielding earnings per share of 10.15. EBITDA reached 7.68B, while operating income came in at 6.55B.

Over the twelve months ended June 30, 2026, Anthem Biosciences Limited posted a gross margin of 63.66, reflecting its pricing power and cost economics. The operating margin of 32.73 and net profit margin of 28.76 provide insight into operational efficiency.